Royce practices food and drug law with a focus on advising pharmaceutical, cosmetic, medical device, cannabis, dietary supplement, tobacco, food and beverage companies as well as investment firms on a range of regulatory matters. He is presently the co-lead of the Cannabis, Hemp, and CBD industry team.
Royce has experience handling complex issues that arise in industries regulated by FDA, USDA, DEA, FTC, EPA, state cannabis regulators, board of pharmacy, Alcohol and Tobacco Tax and Trade Bureau (TTB), and United States Centers for Medicare and Medicaid (CMS).
He has worked with businesses on complex issues regarding drug and food labeling, cannabis compliance, product recalls, food contamination, theft of controlled substances, importation of drugs and medical devices, and criminal violations of the Food Drug and Cosmetics Act (FDCA). Royce has significant experience with FDA enforcement matters responses including crafting response strategies for FDA inspection Form 483’s and Warning Letters.
Both as a former in house attorney and as a member of the firm’s life sciences team Royce works with pharmaceutical and device companies regarding product promotion, labeling, unapproved drugs, competitor products, NDAs, ANDAs, Over The Counter (OTC) drugs, securities filings, clinical trials, drug pricing, federal supply schedules, PhRMA Code and AdvaMed Code compliance, and board of pharmacy registrations.
Royce is plugged in on the ground level in the evolving legal landscape of cannabis and controlled substances. Advising clients on issues pertaining to cannabis transactions, state regulation, product labeling, operational compliance, banking, for direct and indirect Cannabis related industries including CBD, Hemp, and Marijuana product. He has advised and aided numerous banks in crafting policies and procedures for this emerging industry.
Prior to joining McGuireWoods, Royce served as an extern at INTERPOL, the EPA Office of Enforcement and Compliance Assurance (OECA), worked for an Institutional Review Board (IRB) and served as the Associate Counsel for Regulatory Affairs at a drug, medical device, and dietary supplement company. In this position, he oversaw all regulatory aspects from manufacture to marketing of the company’s products, including overseeing four successful branded pharmaceutical product launches. Royce presently advises on a range of issues including;
- FDA regulation, enforcement, inspections, and due diligence of companies;
- Cannabis and Hemp sales, distribution, labeling, and state compliance;
- Premarket Tobacco Product Applications (PMTA) and Electronic Nicotine Delivery Systems (ENDS);
- USDA inspections, regulations, and due diligence of companies;
- Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) guidance;
- Alcohol labeling and taxation compliance;
- Compliance with the Federal Analogue Act;
- Drug and active pharmaceutical ingredient importation;
- Human subject protection and clinical drug trials;
- Medical device manufacturing and post-market safety;
- Drug and pharmaceutical product marketing, labels, pharmacovigilance, adverse events, and labeling;
- Food safety, labeling, and manufacturing issues;
- Food Safety Modernization Act (FSMA);
- Comprehensive Laboratory Improvement Act (CLIA) accreditations, home testing, and licensure of laboratories;
- Drug treatment and Substance Abuse and Mental Health Services Administration (SAMHSA);
- Physician dispensing, physician disciplinary issues, drug theft, and off-label drug use;
- Human and veterinary compounding pharmacies, 503A and 503B outsourcing facilities;
- FDA Food Contact Surfaces and EPA regulated insecticides;
- Human tissue banking and tissue sales;
- Software as a medical device;
- Cannabis banking and compliance;
- Wholesale generic drug sales;
- Securities and Exchange Commissions (SEC) regulated publicly traded life sciences companies;
- State regulation of telemedicine and electronic drug prescribing laws;
- Promotional review committee for drug product labels and labeling;
- State Boards of Pharmacy and manufacturing and wholesale licensure;
- Prescription Drug Marketing Act (PDMA);
- Federal Anti-Kickback;
His past in-house experience gives him insight into the complex mechanics and challenges healthcare and life sciences companies face in growth, compliance, supply, marketing, and manufacturing. He blends legal strategy with business sense to construct practical solutions that match the needs of clients in these heavily regulated industries.
In addition to his current practice, Royce handles pro bono cases for veterans in order to seek benefits for injuries sustained in service and correct service records.
“My time spent in industry gives me a business minded approach to law and my clients. By knowing the client’s business and caring about their products I am able to solve legal issues to advance the business solution.”
Experience
- Advised underwriters B. Riley Securities Inc. and Roth Capital Partners in a $35.2 million IPO of Journey Medical Corp.
- Representation of B. Riley FBR, Inc. (formerly FBR Capital Markets & Co.) as placement agent in connection with the extension of its existing relationship with Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company.
- Representation of Alliance Global Partners (AGP), a regional investment and advisory firm providing investment advisory and brokerage services to individuals and institutions, in connection with the launch of an at-the-market program in which AGP serves as placement agent to ProPhase Labs, Inc. (Nasdaq: PRPH), a manufacturing and marketing company with experience with OTC consumer healthcare products and dietary supplements.
- Representation of National Securities Corp., acting as exclusive placement agent, in connection with a private offering and sale of preferred stock by Cyprium Therapeutics, Inc., a clinical-stage biopharmaceutical company.
- Advised multiple banks on requirements and federal law for banking Marijuana and Hemp businesses.
- Aided in the drafting and review of Premarket Tobacco Application (PMTA) for a novel nicotine product for modified risk use tobacco product.
- Organized document review and designed policies for large scale advocacy project for redaction of confidential client information within FDA applications under Freedom of Information Act (FOIA) exemptions.
- Filed and aided on issues of FOIA in litigation.
- Managed USDA and FDA diligence for the successful acquisition of a national manufacturer of snack products.
- Assisted in state and local food safety compliance diligence for the successful acquisition of national restaurant chains.
- Designed compliance programs for emerging plant based food products for a major international manufacturer.
- Added in the security filing review for multiple publicly traded companies with regards to their statements involving drug efficacy, clinical trials, and competition.
- Drafted policies and procedures for medical device, food, beverage, and pharmaceutical companies.
- Served as regulatory counsel on class action food product liability litigation involving allegations of consumer fraud.
- Advised multiple publicly traded life sciences companies and private equity funds in mergers and acquisitions, conducting comprehensive due diligence to spot and correct problems.
- Lead the legal review for the joint-development of a biosimilar.
- Advised on hemp and hemp extract products at the state and federal levels.
- Advised food and beverage companies for the manufacture of Over The Counter (OTC) hand sanitizer during the COVID-19 Emergency.
- Added in importation of medical devices, masks, and drugs during the COVID-19 Emergency and associated issues with United States Customs and Border Protection (CBP).
- Registered and listed multiple companies and their products on FDA CDER Direct and FURLS.
- Assisted as regulatory counsel in the defense of criminal violations of the Food, Drug, and Cosmetics Act.
- Provided guidance and resolved issues arising with suspected carcinogenic chemicals in human food.
- Represented companies before FDA on issues of drug recall, importation, and product compliance.
- Solved state licensure issues for manufacturers and wholesalers of drug products before state board of pharmacy.
- Trained pharmaceutical sales representatives on current law as it relates to the promotion of drug products.
- Aided defense team as regulatory counsel on a drug product liability claim involving birth-defect.
- Effected change at the local level and in public meetings advocating for policies to advance the ability to market pharmaceutical products.
- Advised on prescription and over the counter drug and dietary supplement labels, labeling, and promotion as the legal representative for the promotional review committee of a pharmaceutical company, overseeing all promotional materials and product labeling.
- Regulatory counsel on five separate Lanham Act cases involving false claims for drug and dietary supplement products.
- Negotiated pharmaceutical wholesale drug sale agreements and purchase agreements for raw materials enabling sales team to $200 million dollar sales targets.
- Created a comprehensive product legal and regulatory database for company for current products and labeling.
- Emory University School of LawLLM2015
- University of Denver Sturm College of LawJD2013
-
Goucher CollegeBAHistory
magna cum laude
2010
Founding Member, The Psychedelic Bar Association
Member, Editorial Advisory Board, FDLI Update, Food and Drug Law Institute, 2020-present
- Speaker, Food and Product Labeling and Sales Practices Litigation and Regulatory Update, March 23, 2023
- Speaker, Food and Product Labeling Litigation and Regulatory Update, October 20, 2022
- Co-moderator, "Cannabis Investment After the Rush: What Does Cannabis Look Like as a Sustained Industry?", 15th Annual Healthcare Finance and Growth Conference, September 15, 2022
- Speaker, Food and Product Labeling Litigation and Regulatory Update, June 8, 2022
- Speaker, Food and Product Labeling Litigation and Regulatory Update, March 29, 2022
- Speaker, Food and Product Labeling Litigation and Regulatory Update, December 2, 2021
- Guest Speaker, "Digital Health Trends and Issues for Life Sciences Companies", Health+Tech Video Podcast Series, October 13, 2021
- Co-host, "Cannabis Litigation and Enforcement Update", Edible Bites Episode 10: Cannabis and Life Sciences Video Webinar Series, October 4, 2021
- Speaker, Edible Bites: Cannabis and Life Sciences Video Webinar Series, Ongoing Series
- Speaker, Food and Product Labeling Litigation and Regulatory Update, September 23, 2021
- Co-host, "Emerging Issues in Cannabis Privacy", Edible Bites Episode 9: Cannabis and Life Sciences Video Webinar Series, August 12, 2021
- Co-host, "Impact of Cannabis Legalization on Government Contractors", Edible Bites Episode 8: Cannabis and Life Sciences Video Webinar Series, July 22, 2021
- Co-host, "Oregon Psilocybin Services Act, Measure 109", Edible Bites Episode 7: Cannabis and Life Sciences Video Webinar Series, June 8, 2021
- Speaker, Food and Product Labeling Litigation and Regulatory Update, May 26, 2021
- Speaker, "Key Developments and Trending Topics on the FDA", Healthcare and Life Sciences Webinar Series, May 20, 2021
- Co-host, "Cannabis Business and Taxes Under IRC Section 280E", Edible Bites Episode 6: Cannabis and Life Sciences Video Webinar Series, May 13, 2021
- Co-host, "Weed at Work: Employment Law Trends", Edible Bites Episode 5: Cannabis and Life Sciences Video Webinar Series, April 13, 2021
- Co-host, "Extended Wrap Edition – Lighting Up the Adult Use Market", Edible Bites Episode 4: Cannabis and Life Sciences Video Webinar Series, March 9, 2021
- Speaker, Food and Product Labeling Litigation and Regulatory Update, February 18, 2021
- Co-host, "FDA Compounding Pharmacy MOU", Edible Bites Episode 3: Cannabis and Life Sciences Video Webinar Series, February 9, 2021
- Speaker, The Times They Are A-Changing, January 27, 2021
- Co-host, "FDA Guidance on Microneedling Products", Edible Bites Episode 1: Cannabis and Life Sciences Video Webinar Series, January 12, 2021
- Co-host, Edible Bites Episode 1: Cannabis and Life Sciences Video Webinar Series, December 10, 2020
- Speaker, Food and Product Labeling Litigation and Regulatory Update, Complimentary Webinar, October 15, 2020
- Speaker, Food and Product Labeling Litigation and Regulatory Update, Complimentary Webinar, June 24, 2020
- Speaker, Food and Product Labeling Litigation and Regulatory Update, Complimentary Webinar, February 19, 2020
- Speaker, CBD Class Actions — Growing Concerns for the Industry and the Next Big Target for the Plaintiffs’ Bar, Complimentary Webinar, Thursday, January 16, 2020
- Moderator, "Regulating Cannabis and CBD Today: State Uncertainty and Federal Restraint" and "Cannabis and CBD and Due Diligence: Legal Considerations and Solutions", Legal Landscape of Cannabis, November 14, 2019
- Speaker, "Really Green Banking: Cannabis Financial Transaction Considerations", Peer Bank Legal Network, October 23, 2019
- Speaker, Food and Product Labeling Litigation and Regulatory Update, Complimentary Webinar, October 22, 2019
- Panelist, "Opioid Crisis: Managing Patients with Pain and Substance Use Disorders", South Florida MGMA 5th Annual Symposium Survey, August 16, 2019
- Speaker, Food and Product Labeling Litigation and Regulatory Update, Complimentary Webinar, May 15, 2019
- Moderator, "FDA Update: Recent Developments and New Initiatives", 10th Annual Pharmaceutical and Medical Device Conference, November 15, 2018
- Panelist, DKBIO 2018 – Danish Science & The City Boston Edition, Boston, MA, April 10 - 11, 2018
- Panelist, "Retail, Specialty, Compounding and Other Pharmacy Investment Opportunities", 15th Annual Healthcare and Life Sciences and Private Equity and Finance Conference, February 21, 2018
- Illinois
- Georgia
- Colorado
- U.S. District Court for the Eastern District of Washington
- U.S. District Court for the District of Colorado
- U.S. District Court for the Southern District of Illinois
- U.S. Court of Appeals for Veterans Claims
- U.S. District Court for the Northern District of Illinois
Named a “Cannabis Law Trailblazer“, The National Law Journal, 2020
Deal Team Leader, “Healthcare/Life Sciences Deal of the Year,” The M&A Advisor, 2022
- Author, HHS Rescheduling, SAFER Banking Act May Change the Marijuana Landscape, McGuireWoods Legal Alert, November 14, 2023
- Author, FDA Proposes Brominated Vegetable Oil Ban, McGuireWoods Legal Alert, November 6, 2023
- Author, HHS Proposes Updates to 20-Year-Old Public Health Service Policies on Research Misconduct, McGuireWoods Legal Alert, October 18, 2023
- Author, California Bans Four Common Food Additives and 26 Chemicals Used in Cosmetics, McGuireWoods Legal Alert, October 16, 2023
- Author, FDA Publishes New Guidance on Cybersecurity in Medical Devices, McGuireWoods Legal Alert, October 2, 2023
- Author, FDA Issues Draft Guidance for Cosmetic Product Listing and Facility Registration, McGuireWoods Legal Alert, August 24, 2023
- Author, Private Equity in Healthcare – An Updated Review of Selected Niche Investment Areas, McGuireWoods Legal Alert, August 7, 2023
- Author, Contract Research Organization Acquisitions: Critical Due Diligence Pathways, McGuireWoods Legal Alert, August 7, 2023
- Author, Breaking The Stigma and Reaping The Medical Benefits: Decriminalizing Psilocybin, McGuireWoods Legal Alert, July 6, 2023
- Author, In the Weeds: California Shuts Down Illegal Cannabis Operation, New York Bans Smoking in Public Parks, McGuireWoods Legal Alert, August 11, 2022
- Author, Delta-8 Debate: Employment and Trademark Litigation in CBD and Cannabis Reaches New High, McGuireWoods Legal Alert, July 29, 2022
- Author, In the Weeds: Cannabis Clinical Trial Expands, Topicals Often Mislabeled, High Potency May Mean High Addiction, McGuireWoods Legal Alert, July 27, 2022
- Author, D.C. Will Protect Employees Who Use Recreational Cannabis, McGuireWoods Legal Alert, July 20, 2022
- Author, In the Weeds: D.C. Allows Adults to Self-Prescribe Medical Marijuana, NY Warnings, Oregon Bans Delta-8 THC Products, McGuireWoods Legal Alert, July 13, 2022
- Author, Considerations for Healthcare Entities and Employers After Roe v. Wade Reversal, McGuireWoods Legal Alert, July 8, 2022
- Author, In the Weeds: Top Court Declines Workers’ Compensation Case, MLB Permits CBD Sponsorship, Buyer Beware Delta-9, McGuireWoods Legal Alert, July 1, 2022
- Author, In the Weeds: Missouri Settles With Producers, Treasury Seeks Input on Marijuana Businesses, McGuireWoods Legal Alert, June 15, 2022
- Author, In the Weeds: FDA Warns Against CBD for Food-Producing Animals, Okla. Suspends Lab License, Calif. Launches Cannabis Access Map, McGuireWoods Legal Alert, June 1, 2022
- Author, In the Weeds: FDA Delta-8 Warning, Cannabis Company Sponsorship, DoorDash Cannabis Delivery in Canada, McGuireWoods Legal Alert, May 18, 2022
- Author, FDA Proposes Standards Banning Flavored Cigars and Menthol Cigarettes, McGuireWoods Legal Alert, May 13, 2022
- Author, In the Weeds: Va. Delta-8 Ban Vetoed, Request to Ban “Copycat” THC Edibles, Calif. Emergency THC Rules, McGuireWoods Legal Alert, May 4, 2022
- Author, California Court: Fair Market Value Payments May Not Avert Anti-Kickback Liability, McGuireWoods Legal Alert, May 3, 2022
- Author, In the Weeds: The 4/20 Edition — Va. Medical Use, Two Delta-8 Bans, NY Cannabis Banking and Tax Deductions, McGuireWoods Legal Alert, April 20, 2022
- Author, FDA Proposes National Standards for Wholesale Drug Distributors and Third-Party Logistics Providers, McGuireWoods Legal Alert, April 15, 2022
- Author, In the Weeds: MORE Act Advances in Congress, Bright Green Registers Shares in U.S., FDA Warns CBD Sellers, McGuireWoods Legal Alert, April 6, 2022
- Author, In the Weeds: Connecticut’s Licensing Lottery, Illinois’ Delays, Michigan Universities to Study Cannabis, McGuireWoods Legal Alert, March 24, 2022
- Author, In the Weeds: N.H. May Protect Worker Use; Feds Weigh Hemp THC Limits; Can Utility Power Marijuana Facilities?, McGuireWoods Legal Alert, March 9, 2022
- Author, In the Weeds: Pennsylvania Says Don’t Inhale, Cease and Desist Letters in New York, Washington Robberies Cause Concern, McGuireWoods Legal Alert, February 23, 2022
- Author, In the Weeds: Mississippi OKs Medical Use, Illinois Might Limit THC, 1st Circuit Allows Prosecution of Growers, McGuireWoods Legal Alert, February 9, 2022
- Author, FDA Guidance Clarifies Classification of Combination Drug-Device Products, McGuireWoods Legal Alert, February 2, 2022
- Author, In the Weeds: DEA Hemp Rule Dispute, Landowners Fined for Tenants’ Crop, Dispensary Workers Seek Union, Feds Address Marijuana Use, McGuireWoods Legal Alert, January 26, 2022
- Author, A Quick Dab — Ohio’s New Telehealth Rules Cover Exams for Medical Marijuana Use, McGuireWoods Legal Alert, January 18, 2022
- Author, A Quick Dab — Ohio Seeks to Codify Legal Delta-8; Proposed Rule Hearing Set for Jan. 18, McGuireWoods Legal Alert, January 14, 2022
- Author, In the Weeds: New Laws for 2022, Kansas Weighs Delta-8, Maine Appeals Dispensary Ruling, Nevada Approves Lounges, McGuireWoods Legal Alert, January 12, 2022
- Author, In the Weeds: Employer Reimbursement of Medical Marijuana, THC Mislabeled as CBD, Possible Legislation in Iowa, McGuireWoods Legal Alert, December 29, 2021
- Author, In the Weeds: CDC on Hired Drivers Using Cannabis, Ordering by App in Ontario and Delta-8 Testing, McGuireWoods Legal Alert, December 15, 2021
- Author, In the Weeds: New and Planned Standards for Hemp Seed, CBD; NY Subways Ban Ads; Colorado Steps Up Enforcement, McGuireWoods Legal Alert, December 1, 2021
- Author, In the Weeds: Billboard Battles, NY Bans but DEA Allows Some Delta-8, Montana Outlaws Dispensary CBD Sales, McGuireWoods Legal Alert, November 16, 2021
- Author, In the Weeds: Kansas Seizes In-Transit Cannabis Profits, USPS Bans CBD Vape Devices, Promotional Gifting Illegal in NY, McGuireWoods Legal Alert, November 4, 2021
- Author, In the Weeds: Cannabis and the Workplace, Missouri Licensing, California Antitrust Case, Oregon THC Test Results, McGuireWoods Legal Alert, October 19, 2021
- Author, A Quick Dab — New California Law Requires Healthcare Facilities to Permit Medical Cannabis Use, McGuireWoods Legal Alert, October 14, 2021
- Author, In the Weeds: Delta-8 Warnings, Cannabis Use for Athletes and Use in California Healthcare Facilities, McGuireWoods Legal Alert, October 5, 2021
- Author, In the Weeds: Illegal Grow Operations, Cannabis Control Rules and Dispensary License Caps, McGuireWoods Legal Alert, September 22, 2021
- Author, In the Weeds: New USDA Hemp Survey, FBI Allegedly Investigates State Licensing and DEA Raises Production Quotas, McGuireWoods Legal Alert, September 7, 2021
- Author, In the Weeds: Highlights in the Budding Cannabis, Hemp and CBD Industries, McGuireWoods Legal Alert, August 24, 2021
- Author, Update on Cannabis Administration and Opportunity Act, McGuireWoods Consulting LLC, July 21, 2021
- Author, New Georgia Statute Prohibits Patient Brokering for Substance Abuse Providers, McGuireWoods Legal Alert, July 19, 2021
- Author, New Laws and the 2021 Cannabis Effect on Employers, McGuireWoods Legal Alert, April 19, 2021
- Author, Beware Dietary Deceit: FDA Warns Companies Allegedly Involved in Misrepresenting Supplements, McGuireWoods Legal Alert, February 26, 2021
- Author, BEWARE of “Operation CBDeceit”, McGuireWoods Legal Alert, January 27, 2021
- Author, Financial Regulators Update Guidance for Hemp-Related Business Banking: Seven Key Points, McGuireWoods Legal Alert, July 28, 2020
- Author, FDA Approves First COVID-19 Test for Sample Pooling, McGuireWoods Legal Alert, July 24, 2020
- Author, Got More Hand Sanitizer? (Part 2) More Legal and Business Considerations for New Market Entrants, McGuireWoods Legal Alert, July 14, 2020
- Author, FDA Asks Industry to Shoot for the Stars in Enhancing the Orange Book, McGuireWoods Legal Alert, July 1, 2020
- Author, One of These Things Is Not Like the Others: FDA Flexibility With Food Ingredients During COVID-19, McGuireWoods Legal Alert, June 1, 2020
- Author, Executive Order Requires Continued Operation of Meat and Poultry Industries, McGuireWoods Legal Alert, April 30, 2020
- Author, Pharmacy Developments Related to COVID-19 Testing and Compounding of Critical Drugs, McGuireWoods Legal Alert, April 27, 2020
- Author, FDA Relaxes Nutrition Labeling Requirements for Restaurants During COVID-19, McGuireWoods Legal Alert, April 16, 2020
- Author, Some States Relax Regulation of Medical and Recreational Cannabis During COVID-19 Crisis, McGuireWoods Legal Alert, April 14, 2020
- Author, FDA Suspends Some Restrictions to Facilitate Veterinary Telemedicine Amid COVID-19 Crisis, McGuireWoods Legal Alert, April 6, 2020
- Author, State Boards Ease Regulations for Pharmacy Practitioners During COVID-19 Pandemic, McGuireWoods Legal Alert, April 2, 2020
- Author, Due to COVID-19, Federal Agencies Reduce Barriers to Controlled Substances and Increase Access to Care, McGuireWoods Legal Alert, March 31, 2020
- Author, USDA Decides It’s Time to Talk “Healthy” on Food Labels: Implications for Industry and Claims, McGuireWoods Legal Alert, March 31, 2020
- Author, CARES Act Modernizes Over-The-Counter Drug Monograph Process, McGuireWoods Legal Alert, March 30, 2020
- Author, FDA’s Emergency Use Authorization Process for COVID-19 Tests May Alleviate Shortage, McGuireWoods Legal Alert, March 25, 2020
- Author, Pharmacists Urged to Curtail Off-Label Prescribing for Experimental COVID-19 Treatments, McGuireWoods Legal Alert, March 24, 2020
- Author, Got Hand Sanitizer? Business and Legal Considerations for New Market Entrants, McGuireWoods Legal Alert, March 24, 2020
- Author, Countermeasures and Why They Matter for Liability During COVID-19, McGuireWoods Legal Alert, March 21, 2020
- Author, FDA’s Dual Approach to Enforcing Federal Food, Drug, and Cosmetics Act During COVID-19 Crisis, McGuireWoods Legal Alert, March 21, 2020
- Author, FDA Changes Position on Clinical Trials and Respirators During COVID-19 Crisis, McGuireWoods Legal Alert, March 19, 2020
- Author, Food Safety During COVID-19 Pandemic: FDA to Relax Some Requirements, USDA Inspections Continue, McGuireWoods Legal Alert, March 18, 2020
- Author, How Hot Is That Crop? USDA Changes Laboratory and Disposal Requirements for Hemp, McGuireWoods Legal Alert, March 11, 2020
- Author, One Fish, Two Fish, Red Fish, Drugs Are Fish? Decision Shows FDCA’s Broad Definition of “Drug”, McGuireWoods Legal Alert, February 21, 2020
- Author, House Energy and Commerce Committee Subcommittee on Health: Cannabis Policies for the New Decade, McGuireWoods Legal Alert, January 17, 2020
- Author, Cannabis and CBD in 2020: 10 Key Takeaways From MJBizCon, McGuireWoods Legal Alert, January 9, 2020
- Author, House Passes Drug Legislation – Senate Tweaks Proposals, McGuireWoods Legal Alert, December 17, 2019
- Author, THC and California Proposition 65: What’s in Store for CBD Product Labeling?, McGuireWoods Legal Alert, December 10, 2019
- Author, FDA to Prioritize Enforcement Actions Against Unapproved Homeopathic Drugs, McGuireWoods Legal Alert, November 26, 2019
- Author, FDA Releases Draft Guidance on Transdermal and Topical Delivery Systems, McGuireWoods Legal Alert, November 26, 2019
- Author, Key Takeaways From McGuireWoods’ Food and Beverage and Private Equity Update, McGuireWoods Legal Alert, November 8, 2019
- Author, House of Representatives Continues to Pass Rx Drug Price Reform Legislation, McGuireWoods Legal Alert, October 31, 2019
- Author, More Time to Label — FDA Announces Enforcement Discretion, Updates Nutrition and Supplement Facts Implementation, McGuireWoods Legal Alert, October 29, 2019
- Author, House Committees Bring Pelosi’s Drug Bill to Floor; Action Expected by Late November, McGuireWoods Legal Alert, October 29, 2019
- Author, FDA Center for Devices and Radiological Health Releases 2020 Guidance Priorities List, McGuireWoods Legal Alert, October 21, 2019
- Author, Potential Impact of Pelosi’s Bill on the Pharmaceutical Industry, McGuireWoods Legal Alert, October 16, 2019
- Author, FTC Continues Crackdown on CBD Marketing Practices, McGuireWoods Legal Alert, September 16, 2019
- Author, Investing in a CBD Business: Five Regulatory Concerns, McGuireWoods Legal Alert, June 17, 2019
- Author, Five Things to Know About CBD — Food, Drugs and the In-Between, McGuireWoods Legal Alert, May 31, 2019
- Author, Direct-to-Consumer Drug Pricing Disclosures Effective July 2019 — 3 Things to Know, McGuireWoods Legal Alert, May 22, 2019
- Author, Dermatology Investment: Getting Staffing, Compensation, and Physician Benefits Just Right – 5 Key Takeaways, The Healthcare Investor, May 16, 2019
- Author, 5 Key Takeaways on Top Surgical Specialty Investments, The Healthcare Investor, March 19, 2018
- Co-author, Medical Device Basics, Glaucoma Research and Clinical Advances 2016 to 2018, 2016